Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.33 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | STAT6 | P42226 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL771417 | 0.92 | KMT2A (0.39) | CHRNA7ALDH1A1SMN1; SMN2KDM4EGAA | |
| SCHEMBL84808 | 0.83 | CHRNA7 (0.48) | CHRNA7ALDH1A1SMN1; SMN2KDM4EGAA | |
| SCHEMBL6657817 | 0.83 | CHRNA7 (0.48) | CHRNA7ALDH1A1SMN1; SMN2KDM4EGAA | |
| SCHEMBL577415 | 0.83 | CHRNA7 (0.48) | CHRNA7ALDH1A1SMN1; SMN2KDM4EGAA | |
| SCHEMBL11501665 | 0.83 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2STAT6 | |
| SCHEMBL262312 | 0.83 | — | — | |
| SCHEMBL577052 | 0.83 | CHRNA7 (0.48) | CHRNA7ALDH1A1SMN1; SMN2KDM4EGAA | |
| SCHEMBL23772 | 0.83 | — | — | |
| Iodide SCHEMBL11554007 | 0.79 | CHRNA7 (0.46) | CHRNA7ALDH1A1SMN1; SMN2KDM4EGAA | |
| Hydrochloric Acid SCHEMBL14482129 | 0.79 | CHRNA7 (0.46) | CHRNA7ALDH1A1SMN1; SMN2KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219495-A1 | AHR MODULATORS | Ideaya Biosciences, Inc. (US) | 2023-08-02 | — | — | EP | claimed |
| EP-3749669-B1 | AHR MODULATORS | IDEAYA BIOSCIENCES INC (US) | 2023-03-08 | — | — | EP | claimed |
| EP-3298011-B1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2021-11-17 | — | — | EP | claimed |
| EP-3749669-A1 | AHR MODULATORS | Ideaya Biosciences, Inc. (US) | 2020-12-16 | — | — | EP | claimed |
| CN-111683950-A | AhR modulators | 伊迪亚生物科学有限公司 | 2020-09-18 | — | — | CN | claimed |
| CN-107652289-B | Substituted tricyclic compounds as FGFR inhibitors | 因塞特控股公司 | 2020-07-21 | — | — | CN | claimed |
| WO-2019156987-A1 | AhR MODULATORS | IDEAYA BIOSCIENCES, INC. (US) | 2019-08-15 | — | — | WO | claimed |
| US-10294260-B2 | Tetracyclic anthraquinone derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2019-05-21 | — | — | US | claimed |
| US-20190127376-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | INCYTE CORPORATION | 2019-05-02 | — | — | US | claimed |
| EP-3176170-B1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | INCYTE HOLDINGS CORP (US) | 2018-11-14 | — | — | EP | claimed |
| EP-1838712-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2007-10-03 | — | — | EP | claimed |
| WO-2006064196-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | claimed |
| EP-1647555-A1 | THE C-GLYCOSYLISOFLAVONES HAVING ALKYLAMINOALKOXYL SUBSTITUENT, THE PREPARATION AND THE USE OF THE SAME | Institute of Radiation Medicine Academy of Military Medical Sciences of the Pla (CN) | 2006-04-19 | — | — | EP | claimed |
| US-4958024-A | REACTION OF CARBAMATE SUBSTITUTED ACRYLIC ESTER, VASODILATORS, HYPOTENSIVE AGENTS | BANYU PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-09-18 | — | — | US | claimed |
| US-4914227-A | FOR VASODILATING AND HYPOTENSIVE AGENTS | BANYU PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-04-03 | — | — | US | claimed |
| US-4739106-A | VASODILATION, HYPOTENSIVE AGENTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1988-04-19 | — | — | US | claimed |
| EP-0101023-B1 | PROCESS FOR PREPARING 2-CARBAMOYLOXYALKYL-1,4-DIHYDROPYRIDINE DERIVATIVES AND INTERMEDIATES USEFUL FOR THE PROCESS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1987-07-29 | — | — | EP | claimed |
| EP-0101023-A1 | Process for preparing 2-carbamoyloxyalkyl-1,4-dihydropyridine derivatives and intermediates useful for the process | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1984-02-22 | — | — | EP | claimed |
| US-4404378-A | HYPOTENSIVE AGENTS; VASODILATION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1983-09-13 | — | — | US | claimed |
| EP-0063747-A1 | 2-Substituted or unsubstituted aminocarbonyloxyalkyl-1,4-dihydropyridines | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1982-11-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294260-B2 | Tetracyclic anthraquinone derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, F12, ANTXR2 | CHRNA7 4592/4885ALDH1A1 736/4885SMN1; SMN2 2232/4885 |
| US-20190127376-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | FGFR3, FGFR1, FGFR2 | CHRNA7 4883/4885ALDH1A1 586/4885SMN1; SMN2 4636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.